Anixa Biosciences ANIX 深 沪
已收盘 08-21 16:00:00 美东时间
3.71
+0.120
+3.34%
华盛通- 最 高3.755
- 今 开3.64
- 成交量 18.24万股
- 最 低 3.60
- 昨 收 3.59
- 总市值 1.26亿
- 52周最高 5.4566
- 市盈率 静 --
- 换手率 0.54%
- 52周最低 2.32
- 委 比 42.28%
- 总股本 3402.31万
- 历史最高 8.09
- 量 比 0.71
- 振 幅 4.32%
- 历史最低 1.33
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 mo...
08-18 20:45
Anixa Biosciences乳腺癌疫苗技术获澳大利亚专利批准
Anixa Biosciences（股票代码：ANIX）今日宣布，其开发的乳腺癌疫苗技术已获得澳大利亚专利局的专利批准。这一进展标志着该公司在全球知识产权布...
07-14 23:51
Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of Acceptance for a new patent related to Anixa's breast cancer vaccine technology.
07-14 20:35
Anixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT053...
07-06 20:36
Anixa Biosciences Announces Its Breast Cancer Vaccine's Final Phase 1 Data Shows All Major Primary Endpoints Met, Protocol-Defined Immune Responses Generated In 74% Of Participants
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its two clinical-stage immunotherapy programs were presented at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy sympos...
06-26 21:13
Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 22.22 percent increase over losses of $(0.09) per share from the same period last year.
06-11 05:31
Anixa Biosciences Secures Canadian Patent Allowance For AMHR2-Targeting Ovarian Cancer Vaccine Technology
Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancerSAN JOSE, Calif., June 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or
06-01 21:10
Anixa Biosciences Announces Its Data From Phase 1 Clinical Study Of Liraltagene Autoleucel Demonstrates No Dose-Limiting Toxicities To Treat Recurrent Ovarian Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1
05-11 21:02
